The Philadelphia chromosome, t(9;22), is present in virtually all cases of chronic myeloid leukemia (CML). It has previously been shown by cytogenetic studies that the rearranged chromosome 22 in patients with CML is exclusively maternal in origin. To address this issue at a molecular level, the major breakpoint cluster region (M-bcr) on chromosome 22 was examined using Southern blot assays and M-bcr Pvu HRONIC MYELOID leukemia (CML) is a hematologic malignancy that is virtually always associated with the t(9;22) by cytogenetic analysis. This translocation juxtaposes the BCR gene on chromosome 22 with the c-ab1 oncogene on chromosome 9, producing a hybrid BCRlc-ab1 gene believed essential in the pathogenesis of this disease. ' By using chromosome polymorphisms in families of patients with Philadelphia chromosome-positive CML, Haas et a12 demonstrated a marked "parent of origin" bias in the chromosomes involved in the t(9;22). Without exception, the derivation of chromosome 9 and chromosome 22 in this translocation was paternal and maternal, respectively. This has led to speculation that imprinting may have some role in the mechanism of the translocation.
HRONIC MYELOID leukemia (CML) is a hematologic
malignancy that is virtually always associated with the t(9;22) by cytogenetic analysis. This translocation juxtaposes the BCR gene on chromosome 22 with the c-ab1 oncogene on chromosome 9, producing a hybrid BCRlc-ab1 gene believed essential in the pathogenesis of this disease. ' By using chromosome polymorphisms in families of patients with Philadelphia chromosome-positive CML, Haas et a12 demonstrated a marked "parent of origin" bias in the chromosomes involved in the t(9;22). Without exception, the derivation of chromosome 9 and chromosome 22 in this translocation was paternal and maternal, respectively. This has led to speculation that imprinting may have some role in the mechanism of the translocation.
To substantiate this finding at a molecular level, the present study used restriction fragment length polymorphisms of the major breakpoint cluster region (M-bcr) in families of CML patients to determine the parental origin of the rearranged M-bcr.
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MATERIALS AND METHODS
Patient and parent material. To be included in this study the following criteria had to be met. (1) The patient had to have a rearrangement detectable by Southern blot in a Bgl I1 and Pvu I1 digest with probes 1 and 2 (infra vide). (2) The patient had to be heterozygous for the M-bcr Pvu I1 or Mae I1 restriction site polymorphi~m.~.~ (3) DNA specimens had to be obtainable from both of the patient's parents. (4) At least one of the parents had to be homozygous for the presence or absence of the M-bcr Mae I1 or Pvu I1 restriction site to produce an informative crossing.
All samples were obtained with approval from and in accordance to the rules governing the University of Minnesota Committee on the Use of Human Subjects in Research. Ten CML patients and their parents from the University of Minnesota were examined for the presence of informative Pvu I1 or Mae I1 polymorphisms. Of these, three met the above criteria. The clinical characteristics of these patients are shown in Table 1 . Southern blots. Peripheral blood and/or bone marrow cells from patients and parents were lysed in TNE (10 mmoVL Tris-Cl, pH 8.0, 100 mmoVL NaCI, 1 mmoVL EDTA) buffer in the presence of 1% sodium dodecyl sulfate and genomic DNAs from these specimens were purified by standard methods followed by ethanol precipitation.
Two aliquots of 5 pg of patient DNA were digested according to manufacturers' recommendations with Pvu I1 and double-digested with Bgl WMae 11, respectively. Fifty units of Pvu I1 and Bgl I1 (Bethesda Research Laboratories Life Technologies, Inc, Gaithersburg, MD) and 15 U of Mae I1 (Boehringer Mannheim, Inc, Indianapolis, IN) were used in the digestions. Electrophoresis was performed in horizontal 0.7% agarose gels. Four micrograms of A phage DNA digested with Bste I1 (Bethesda Research Laboratories Life Technologies, Inc) was included on all gels as a size standard. The manufacturer's methods were used for transfening the electrophoretically separated restriction fragments to GeneScreen Plus nylon membranes (Dupont, Inc. Boston, MA).
The probes and Bste 11-digested A DNA were radiolabeled with "P using the random primer r e a~t i o n .~
The filters were prehybridized, hybridized, stripped, and rehybridized all according to manufacturer's recommendations (GeneScreen Plus; Dupont, Inc). Washes were adjusted to the background radioactivity with a final wash in 1.OX to 0.2X standard saline citrate solution (0.015 moll L NaCI, 0.0075 molL sodium citrate) and 0.1 % sodium dodecyl sulfate at 60°C to 65°C. The filters were exposed to Kodak XAR-5 films (Eastman Kodak CO, Rochester, NY) at -85°C for 24 hours to several days.
Probes. The probes used in this study were either the 5' most Tag IlHindIII 1.4-kb fragment of the M-bcr (probe 1, Fig 1) or the 3' most 1.2-kb HindIIUBgl I1 fragment of the M-bcr (probe 2, Fig 1) . The plasmid containing probe 1 was provided by the American Type Culture Collection (Rockville, MD). The plasmid containing probe 2 was kindly provided by Dr David Leibowitz (Indiana Medical School, Indianapolis, IN). 
RESULTS
A restriction map of the M-bcr with relevant restriction enzyme sites is presented in Fig 1. The results of the three informative families are shown in Figs 2 through 4 and summarized in Table 1 .
Family I (Fig 2) . The absence and presence of the Mbcr Pvu I1 polymorphism manifests as a 4.8-kb and 2.5-kb restriction fragment, respectively, in Pvu 11-digested DNA hybridized with probe 1 (Fig 1) . The mother has both of these restriction fragments and is a heterozygote; the father has only the 4.8-kb fragment and is a homozygote for the of genomic DNA from the patient, the patient's father, and the patient's mother hybridized to the 5' M-bcr probe l (see Fig l) . As in family 1, the patient has inherited the 2.5-kb allele from the mother; the paternal allele is rearranged.
absence of the Pvu I1 site. The child with CML has a 2.5-kb fragment indicating inheritance from the mother. The paternal restriction fragment is 2.9 kb in length and represents the rearranged M-bcr allele. A faint 4.8-kb germline band representing the unrearranged paternal allele in a small (<5%) population of Ph-negative cells is noted in the child. Family 2 (Fig 3) . The mother has 4.8-kb and 2.5-kb Pvu I1 M-bcr restriction fragments with probe 1 and is heterozygous for the Pvu I1 polymorphism. The father has only the 4.8-kb fragment and is homozygous for the absence of the Pvu I1 site. The child with CML has inherited the maternal 2.5-kb fragment; this allele is unrearranged. The paternal allele is rearranged with a length of 2.9 kb.
Family 3 (Fig 4) . The M-bcr Mae I1 polymorphism is approximately 100 bp 5' of the M-bcr Pvu I1 polymorphic site (Fig 1) . This polymorphism manifests as a 2.5-kb Bgl IYMae I1 fragment in Bgl IYMae I1 double-digested genomic DNA hybridized to probes 1 or 2. When the Mae I1 site is absent, a 4.8-kb BgI IYBgl I1 fragment is identified.
The mother is homozygous for the absence of the Mae I1 site and has only 4.8-kb Bgl IYBgl I1 fragments with probe 1. The child with CML and father are heterozygous for the Mae I1 polymorphism with both 4.8-kb Bgl IVBgl I1 and 2.5-kb Bgl IVMae I1 fragments with probe 1. When the same Southern blot was hybridized with probe 2, a 4.8-kb Bgl TV Bgl I1 germline fragment was present in the child's DNA. This fragment lacks the Mae I1 polymorphic site and was inherited from his mother. The rearranged fragment that is 4.0 kb in length is paternal in origin.
DISCUSSION
These data indicate that the paternal major breakpoint cluster region on chromosome 22 (M-bcr) may participate in the t(9;22) at the molecular level. The nature of the translocation did not allow for determination by molecular methods of the parental origin of the rearranged chromosome 9 in these cases. ' The results presented here do not necessarily contradict the results of Haas et al.' Those cytogenetic studies were based on silver staining polymorphisms of the nucleolus organizing region (Ag-NOR) on the short arm of chromosome 22, some distance from the M-bcr. It is possible that a somatic recombinatorial event between the maternally and paternally derived chromosomes 22 in CML patients could be occurring before or during the Philadelphia chromosome translocation; the recombination would occur between the M-bcr on the long arm and the Ag-NOR on the short arm of chromosome 22. The exclusive paternal and maternal origin of the M-bcr and chromosome 22 Ag-NOR elements, respectively, on the Philadelphia chromosome suggests that this event may be a common occurrence. Such a finding may be biologically significant in the genesis of the BCWc-ab1 hybrid gene in CML. Confirmation of this hypothesis will require combined cytogenetic and molecular analysis in individual cases. Alternatively, the exceptional cases presented may implicate other factors besides parental origin in determining the participation of a given chromosome in the t(9;22). It is important to recognize that the cases in the present study represent a small and biased population. The selection criteria include the presence of the Mae I1 or Pvu I1 polymorphism; the latter polymorphism is found exclusively in a small percentage of sibships of patients with CML and other hematologic malignancies? It is possible that these polymorphisms or some property of the M-bcr associated with the polymorphisms may be a more important determinant in chromosomal participation in the t(9;22) than parental origin. Interestingly, the Pvu I1 polymorphism was maternally derived and on the nonrearranged M-bcr in both instances, indicating that whatever function, if any, the polymorphism may play in the translocation, it need not be present on the involved chromosome.
The biologic basis of the chromosomal bias described by Haas et a1' and the exceptions presented here are not currently understood. Those investigators allude to DNA methylation as a possible mechanism for the apparent imprinting of the chromosomes involved in the t(9;22). Supporting this concept, it has previously been shown that cell-specific hypomethylated sites are clustered in those regions of the Mbcr most frequently translocated?' In addition, patients with CML have aberrant methylation patterns of the rearranged M-bcr.6 Whether this aberrancy is the cause or result of the translocation remains to be determined.
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